Stockscreener 앱 받기
3.58
2.71%
0.08
전일 마감가:
$3.50
열려 있는:
$3.51
하루 거래량:
1.29M
Relative Volume:
0.14
시가총액:
$1.21B
수익:
$32.77M
순이익/손실:
$-440.22M
주가수익비율:
-2.1437
EPS:
-1.67
순현금흐름:
$-400.48M
1주 성능:
-0.42%
1개월 성능:
+19.83%
6개월 성능:
-69.17%
1년 성능:
-73.62%
1일 변동 폭
$3.51
$3.73
1주일 범위
$3.32
$3.73
52주 변동 폭
$2.70
$14.23
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
명칭
Iovance Biotherapeutics Inc
전화
(650) 260-7120
주소
825 INDUSTRIAL ROAD, SAN CARLOS
IOVA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
3.5739 | 1.21B | 32.77M | -440.22M | -400.48M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.98 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.55 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
653.63 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.71 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.13 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-07-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | 개시 | Goldman | Buy |
| 2023-09-18 | 재확인 | Barclays | Overweight |
| 2023-05-30 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | 재개 | Wells Fargo | Equal Weight |
| 2023-01-27 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-31 | 개시 | Guggenheim | Neutral |
| 2022-08-18 | 재개 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-12-07 | 재개 | Cowen | Outperform |
| 2021-06-10 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-05-03 | 개시 | Truist | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2021-03-08 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | 개시 | Mizuho | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-02-26 | 재확인 | Oppenheimer | Outperform |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-10-01 | 개시 | Stifel | Buy |
| 2019-04-29 | 개시 | Piper Jaffray | Overweight |
| 2019-02-28 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-07 | 개시 | Robert W. Baird | Outperform |
| 2018-12-31 | 재개 | B. Riley FBR | Buy |
| 2018-07-06 | 재확인 | Chardan Capital Markets | Buy |
| 2018-04-10 | 업그레이드 | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | 재확인 | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-01 | 재확인 | B. Riley FBR, Inc. | Buy |
모두보기
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
Iovance Biotherapeutics (IOVA) Nears Profitability with 2027 Projection - GuruFocus
Iovance Biotherapeutics (IOVA) to Announce Q1 2025 Financial Results - GuruFocus
Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025 | IOVA Stock News - GuruFocus
Iovance Biotherapeutics to Host First Quarter 2025 - GlobeNewswire
Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025 - Yahoo Finance
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Is Expected To Breakeven In The Near Future - Yahoo Finance
Loss-Making Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Expected To Breakeven In The Medium-Term - simplywall.st
2 Beaten-Down Stocks With Incredible Upside Potential - Yahoo
Press Release Distribution & PR Platform - ACCESS Newswire
Iovance Biotherapeutics to Present Pre-Clinical and Five-Year Outcomes Data at 2025 AACR and ASCO Annual Meetings - Nasdaq
Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses - GlobeNewswire
Iovance Biotherapeutics Stock Is Crashing. And Here's Why Things Could Get Even Worse This Year. - MSN
Iovance Biotherapeutics: Only For The Brave (NASDAQ:IOVA) - Seeking Alpha
Commit To Buy Iovance Biotherapeutics At $2.50, Earn 35.1% Annualized Using Options - Nasdaq
Iovance Biotherapeutics (IOVA) Projects Strong Growth with FDA-A - GuruFocus
This Biotech Stock Could Be the Best Investment of the Decade - Yahoo
Is Iovance Biotherapeutics (IOVA) the Most Promising Penny Stock According to Analysts? - Insider Monkey
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | IOVA Stock News - GuruFocus
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ L - GuruFocus
11 Most Promising Penny Stocks According to Analysts - Insider Monkey
Is Iovance Biotherapeutics Inc. (NASDAQ:IOVA) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Yahoo
13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey
Barclays Adjusts Iovance Biotherapeutics (IOVA) Price Target Ami - GuruFocus
Is Iovance Biotherapeutics a Millionaire-Maker? - MSN
Barclays cuts Iovance Biotherapeutics target to $5, keeps rating By Investing.com - Investing.com Canada
Iovance Biotherapeutics (IOVA) Eyes Revenue Growth with TIL Ther - GuruFocus
TILs’ Tomorrow Bringing More Cancers Under Immune Control - Genetic Engineering and Biotechnology News
Iovance Biotherapeutics, Inc. (IOVA): Among Stocks Under $10 that Will Triple - Insider Monkey
10 Stocks Under $10 that Will Triple - Insider Monkey
Trading (IOVA) With Integrated Risk Controls - news.stocktradersdaily.com
Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Iovance Biotherapeutics (NasdaqGM:IOVA) Drops 10% Over The Week In Market Correction - Yahoo Finance
Osteosarcoma Market Set for Groundbreaking Expansion by 2032, Forecasts DelveInsight | Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech - The Globe and Mail
Iovance: Less And Less Likely To Reap Reward From Its Pioneering Work (NASDAQ:IOVA) - Seeking Alpha
Institutional Investors May Adopt Severe Steps After Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Latest 8.3% Drop Adds to a Year Losses - 富途牛牛
Tumor-Infiltrating Lymphocytes Treatment Market Size in 7MM - openPR.com
Uveal Neoplasms Treatment Market Size in 7MM is expected to grow - openPR.com
Tumor-infiltrating Lymphocyte (TIL) Therapies Global Market Report 2025: 75+ Therapies are Under Development and 100+ Clinical Trials are Underway Globally - Yahoo Finance
Cell Therapy Veteran With 16 Successful Launches Joins TScan Leadership - Stock Titan
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access - GlobeNewswire
Top 3 Health Care Stocks That Are Set To Fly This Month - Benzinga
Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) The Top Penny Stock That Will Skyrocket? - Insider Monkey
Iovance Biotherapeutics Inc (IOVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Iovance Biotherapeutics Inc 주식 (IOVA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bellemin Jean-Marc | Chief Financial Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
58,590 |
0 |
87,938 |
| BILINSKY IGOR | Chief Operating Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
62,106 |
0 |
120,880 |
| Vogt Frederick G | Interim CEO & General Counsel |
Mar 03 '25 |
Option Exercise |
0.00 |
223,943 |
0 |
445,059 |
| Puri Raj K. | Chief Regulatory Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
59,999 |
0 |
215,411 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
62,497 |
0 |
126,383 |
| Vogt Frederick G | Interim CEO & General Counsel |
Jan 14 '25 |
Option Exercise |
0.00 |
20,835 |
0 |
231,071 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jan 14 '25 |
Option Exercise |
0.00 |
2,813 |
0 |
65,464 |
| BILINSKY IGOR | Chief Operating Officer |
Jan 14 '25 |
Option Exercise |
0.00 |
2,813 |
0 |
60,352 |
| Puri Raj K. | Chief Regulatory Officer |
Dec 16 '24 |
Option Exercise |
0.00 |
8,334 |
0 |
159,171 |
| Vogt Frederick G | Interim CEO & General Counsel |
Dec 02 '24 |
Option Exercise |
0.00 |
10,417 |
0 |
214,662 |
0.70%
3.92%
자본화:
|
볼륨(24시간):